AUS
NZ
UK
CA
USA
IND
ECS Botanics Holdings Ltd (ASX:ECS), a leading Australian medicinal cannabis cultivator and manufacturer, has scheduled a live investor webinar for Tuesday, 28 July 2026 at 1:00pm AEST. Managing Director Nan-Maree Schoerie will present the company’s June 2026 quarterly report and operational highlights. Shareholders, investors, and brokers are encouraged to join the live session, submit questions, and access a recorded version after the event.
Key Highlights
- ECS Botanics Holdings Ltd (ASX:ECS) operates as a medicinal cannabis cultivator and manufacturer in Northwest Victoria, Australia.
- The company will host a live investor webinar on 28 July 2026 to discuss Q4 FY26 financial results and operational updates.
- Managing Director Nan-Maree Schoerie will deliver the June 2026 quarterly report to shareholders, investors, and brokers.
- Participants can submit questions before or during the Zoom webinar, with a recorded session available post-event.
ECS Botanics’ Licensed Cannabis Manufacturing Facility in Northwest Victoria
Headquartered at 899 River Road, Murrabit West, Victoria 3579, ECS Botanics Holdings Ltd is a licensed medicinal cannabis cultivator and manufacturer. The company holds manufacturing licenses issued by the Australian Therapeutic Goods Administration (TGA) and produces GMP-certified products compliant with PIC/S standards, aligned with European Union regulatory requirements. This accreditation establishes ECS as a compliant operator within Australia’s tightly regulated medicinal cannabis industry, enabling supply of quality-assured products to the domestic market.
The company’s operational approach focuses on sustainable, regenerative cultivation combined with renewable energy usage. ECS employs innovative cultivation techniques aimed at producing premium medicinal cannabis products while prioritising environmental responsibility. This sustainability-driven model distinguishes ECS within the growing Australian medicinal cannabis sector and aligns with industry trends toward eco-friendly production.
GMP Certification and Regulatory Compliance Under the Therapeutic Goods Administration
Operating under stringent oversight from the Australian Therapeutic Goods Administration, ECS Botanics maintains GMP (Good Manufacturing Practice) certification that meets international standards equivalent to PIC/S, recognised by European Union agencies. This certification is essential for manufacturing therapeutic products that meet strict quality, safety, and efficacy criteria, serving as a key competitive advantage.
Ongoing compliance with TGA licensing and GMP standards requires rigorous adherence to manufacturing protocols, documentation, and quality assurance. While these regulatory demands represent operational challenges, they also provide ECS with market credibility and legal standing. The company’s established regulatory status demonstrates its successful navigation of Australia’s complex medicinal cannabis licensing landscape.
Market Positioning and Product Supply Strategy in Australian Medicinal Cannabis
ECS Botanics has positioned itself as a prominent supplier of high-quality, affordable medicinal cannabis products within Australia’s therapeutic market. The company balances product quality with patient affordability, catering to a market that has expanded significantly since medicinal cannabis was legalised in 2016. ECS supplies patients, healthcare practitioners, and pharmaceutical distributors.
The company’s competitive edge lies in combining sustainable cultivation practices with cost-effective manufacturing. Its use of organic, regenerative horticulture and renewable energy appeals to environmentally conscious healthcare providers and patients while maintaining operational efficiency. As the Australian medicinal cannabis sector evolves with maturing regulations and market frameworks, ECS is well placed to meet growing demand.
Q4 FY26 Investor Webinar Details
ECS Botanics will conduct a live investor webinar on Tuesday, 28 July 2026 at 1:00pm AEST. Managing Director Nan-Maree Schoerie will present the June 2026 quarterly report. Shareholders, investors, and brokers can register for the live Zoom session, providing direct access to management’s financial and operational updates.
Registration is available online via Zoom, with confirmation emails including calendar invitations and joining instructions. Attendees may join via web browser video or telephone audio using local dial-in numbers and webinar ID codes. A recorded version will be made accessible shortly after the live event for those unable to attend.
Shareholder Engagement and Question Submission Process
ECS Botanics encourages shareholders and investors to submit questions in advance by emailing [email protected]. This allows management to prepare thorough responses for key investor concerns. Additionally, live questions can be submitted during the webinar via Zoom’s Q&A feature, facilitating both pre-planned and real-time engagement.
This dual question submission process exemplifies best practice in corporate governance and investor relations, ensuring shareholders receive comprehensive insights on quarterly performance, strategic direction, and operational matters.
Access to Post-Webinar Recording for Investors
A recorded version of the webinar will be provided to shareholders and investors soon after the live presentation concludes. This ensures equitable access to quarterly updates and management commentary regardless of attendance. The recording supports ongoing investor analysis, transparency, and informed decision-making.
By archiving the webinar, ECS Botanics offers a permanent reference of management’s discussion on June 2026 results, useful for advisers, analysts, and future strategic review.
Managing Director Nan-Maree Schoerie’s Role in Investor Communications
Nan-Maree Schoerie, Managing Director of ECS Botanics, will personally deliver the Q4 FY26 results and strategic overview during the webinar. Her involvement highlights the importance of the update and management’s direct engagement with shareholders on financial and operational issues.
Her authorisation of the company update under ASX Listing Rules confirms the accuracy and materiality of the information presented, reflecting management’s accountability and transparency.
Context of the Australian Medicinal Cannabis Industry and Growth Prospects
Since the legalisation of medicinal cannabis in 2016, Australia’s sector has matured with defined regulatory oversight by the TGA. Licensed cultivators and manufacturers like ECS Botanics serve a growing patient base accessing cannabis through healthcare practitioners. The industry continues to evolve with increasing patient awareness and healthcare integration.
ECS Botanics’ strong regulatory compliance, market access, and operational capabilities position it as a leading player in this expanding industry. Its focus on sustainable, organic practices aligns with broader trends favoring environmentally responsible pharmaceutical production, appealing to ethical healthcare providers and patients. As the market develops, licensed manufacturers with robust supply chains and quality standards are poised to benefit from rising demand.
Commitment to Investor Communication and Market Transparency
By hosting a dedicated investor webinar for quarterly results, ECS Botanics demonstrates its commitment to transparent and formal investor communication. Such webinars are increasingly common among ASX-listed companies, providing shareholders with direct access to leadership and detailed financial and operational insights.
The scheduled webinar on 28 July 2026 ensures timely disclosure of June 2026 quarterly performance. For investors and analysts tracking ECS Botanics, these sessions offer critical updates on production, sales, regulatory developments, and future guidance. The availability of a recorded webinar further enhances ongoing investor engagement and market transparency.
